Risks of Long-Acting Beta-Agonists in Achieving Asthma Control
- 16 April 2009
- journal article
- editorial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 360 (16), 1671-1672
- https://doi.org/10.1056/nejme0902057
Abstract
In early December 2008, the Food and Drug Administration (FDA) held an unusual joint meeting of the Pulmonary–Allergy Drugs Advisory Committee, the Drug Safety and Risk Management Advisory Committee, and the Pediatric Advisory Committee to consider the safety of long-acting beta-agonists (LABAs). The meeting is described in detail in a Perspective in this issue of the Journal by Kramer,1 who points out that decision making by the advisers and the FDA was hampered by the lack of data about the safety of LABAs.Keywords
This publication has 11 references indexed in Scilit:
- Balancing the Benefits and Risks of Inhaled Long-Acting Beta-Agonists — The Influence of ValuesThe New England Journal of Medicine, 2009
- The Safety of Long-Acting β-Agonists among Patients with Asthma Using Inhaled CorticosteroidsAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Global strategy for asthma management and prevention: GINA executive summaryEuropean Respiratory Journal, 2008
- Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma–Summary Report 2007Journal of Allergy and Clinical Immunology, 2007
- β2 Déjà VuSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006
- The Salmeterol Multicenter Asthma Research TrialSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006
- Safety of Long-Acting Beta-Agonists — An Urgent Need to Clear the AirThe New England Journal of Medicine, 2005
- Can Guideline-defined Asthma Control Be Achieved?American Journal of Respiratory and Critical Care Medicine, 2004
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaThe New England Journal of Medicine, 1997
- Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroidThe Lancet, 1994